about
Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsLoss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.A case-based reasoning system for genotypic prediction of HIV-1 co-receptor tropism.Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismCoreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs.Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.HIV-1 tropism and survival in vertically infected Ugandan infants.Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection.Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study.Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trialsStatin therapy prevents expansive remodeling in venous bypass grafts
P50
Q33685141-533602EE-850C-480A-90F1-F57EF0555D1FQ33810849-25D6803C-4E73-493A-AA23-588BAEDD5D74Q34823507-2CB9E432-5DA1-4812-AD1C-E8108A47AD1FQ35635933-34F8B5EF-FB7C-4A38-B7A1-8EABDF6595A6Q35947561-0E7B2BCD-B743-4414-A307-E91E54FAEFB1Q36191170-C7949C1F-A652-417C-95F7-EEB9CE822057Q36484034-7452E360-E3B7-49D1-8916-C103EE7CDED4Q37247686-98D0AA7D-8A33-4DB2-BB22-C8178CB1AF4AQ37370674-B5022C5B-5525-4E3B-B85D-63CBFD925E63Q37393551-0D7AEA9F-B888-450F-AA16-F6AF138E191CQ38610610-8C38EF1F-478D-4104-8F5B-72403116B321Q38876345-AFBADC13-4C33-4D71-A231-988E209E32C2Q39010836-3177F80C-9A40-4C2D-BA32-07765D8F2D56Q39528024-58C87238-79C8-4FD3-A259-04A9F4D40E2FQ39980493-AE1C66B6-3055-4D09-BF52-1FF9A6CF6411Q41101883-45F01783-6CE0-424C-AE08-E2DBA3B42CDDQ51678979-9D0AE936-0A54-437E-BD87-1043014926F6Q60933971-95287B52-87A9-44D8-A410-EB5B409B4998Q83890625-5F8E227F-41F5-42E4-A430-517A7D087656
P50
name
Jonathan Toma
@en
type
label
Jonathan Toma
@en
prefLabel
Jonathan Toma
@en